FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new compound presented by general formula (I): (wherein R1 represents (1) COOH, (2) COOR2, (3) CH2OH or (4) CONR3R4, R2 represents C1-C6 alkyl group optionally substituted by hydroxy group or C1-4 alkoxy group, each R3 and R4 independently represents hydrogen atom or C1-4 alkyl group optionally substituted by ONO2 group, R5 represents halogen atom, hydroxy group or C1-4 alkoxy group, Z represents (1) -(CH2)m-, (2) -(CH2)n-CH=CH-, (3) -(CH2)p-A-CH2-, (4) phenyl or (5) thiazol, A represents oxygen atom or sulphur atom, W represents C1-6 alkyl group optionally substituted by 1-5 substitutes specified in a group consisting of (1) hydroxy group, (2) oxo group, (3) halogen atom, (4) C1-4 alkyl group, (5) C1-4 alkoxy group, (6) ring 2, (7) -O-ring 2 and (8) -S-ring 2, ring 2 represents phenyl, cyclohexyl or pyridinyl, any of which is optionally substituted by 1-5 substitutes specified in a group consisting of (1) halogen atom, (2) CF3, (3) OCF3, (4) C1-4 alkoxy group, (5) C1-4 alkyl group and (6) hydroxy group, m represents an integer having a value of 1 to 6, n represents an integer having a value of 1 to 4, p represents an integer having a value of 1 to 4, represents a single bond or a double bond, represents α configuration, represents β configuration, and represents α configuration, β configuration or a random mixture thereof, or to its salt or its solvate.
EFFECT: invention refers to using this compound, a based pharmaceutical composition, and to a method for preventing and treating ophthalmic diseases, as possesses the potent and stable action for intraocular pressure reduction, and besides has no side effects on the eyes, such as eye irritation (hyperaemia, corneal opacity, etc), higher protein concentration in the intraocular fluid, and hence possesses higher safety and can be an excellent remedy for preventing and/or treating glaucoma.
11 cl, 13 dwg, 9 tbl, 105 ex
Title | Year | Author | Number |
---|---|---|---|
TRITERPENE DERIVATIVES OF LUPEOL TYPE AS ANTIVIRAL PREPARATIONS | 2010 |
|
RU2561604C2 |
RMT5 INHIBITORS | 2019 |
|
RU2814198C2 |
SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
MACROCYCLIZATION REACTIONS AND INTERMEDIATE COMPOUNDS AND OTHER FRAGMENTS SUITABLE FOR PREPARING ANALOGUES OF HALICHONDRIN B | 2014 |
|
RU2710545C2 |
NEUROTISATION AND PROTECTION AGENT | 2006 |
|
RU2420316C2 |
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
REGULATORS-DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND THEIR USE | 2019 |
|
RU2797408C2 |
TETRAHYDROFURO(3,2-b)PYRROL-3-ONES AS CATHEPSIN K INHIBITORS | 2007 |
|
RU2456290C2 |
NEW PROSTAGLANDIN DERIVATIVE | 2017 |
|
RU2748837C2 |
SPLICEOSTATIN ANALOGS | 2013 |
|
RU2618523C2 |
Authors
Dates
2015-02-10—Published
2010-07-27—Filed